Can we predict who will benefit from liver cancer immunotherapy?

NCT ID NCT06796114

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 27 times

Summary

This study aims to identify biological markers (biomarkers) that can predict outcomes in people with advanced liver cancer treated with the immunotherapy drugs tremelimumab and durvalumab. Researchers will follow 120 participants who have not had prior systemic treatment and are eligible for this therapy in routine care. The goal is to better understand which patients are most likely to benefit, improving personalized treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CH de Chalon sur Saône

    RECRUITING

    Chalon-sur-Saône, France

    Contact

  • CH de Mulhouse

    RECRUITING

    Mulhouse, France

    Contact

  • CHU Grenoble

    RECRUITING

    Grenoble, France

    Contact

  • CHU Poitiers

    NOT_YET_RECRUITING

    Poitiers, France

    Contact

  • CHU de Besançon

    RECRUITING

    Besançon, France

    Contact

  • CHU de Reims

    NOT_YET_RECRUITING

    Reims, France

    Contact

  • Hôpital Beaujon - APHP

    RECRUITING

    Paris, France

    Contact

  • Hôpital Henri Mondor - APHP

    NOT_YET_RECRUITING

    Paris, France

    Contact

  • Hôpital La Pitié Salpêtrière - APHP

    RECRUITING

    Paris, France

    Contact

  • ICANS

    NOT_YET_RECRUITING

    Strasbourg, France

    Contact

Conditions

Explore the condition pages connected to this study.